First report of KPC-35-producing Klebsiella pneumoniae ST258 isolated in Peru

Abstract

Klebsiella pneumoniae sequence type 258 (ST258) is the main cause of the global spread of KPC and a significant public health problem. In 2015, ceftazidime/avibactam (CZA) was introduced as a therapeutic alternative and since it has contributed to the development of new KPC variants. Here we present the identification of two consecutive isolations of K. pneumoniae ST258 (KP1 and KP2), from a patient with urinary tract infection. KP1 and KP2 harbored bla_KPC-2 and bla_KPC-35, respectively. KP2 exhibited a modified susceptibility profile to carbapenems and resistance to CZA. To the best of our knowledge, this is the first report of K. pneumoniae ST258 in Peru, which highlights the increasing problem of CZA resistance.